NASDAQ:CRNX
Crinetics Pharmaceuticals Inc Stock News
$51.40
-0.510 (-0.98%)
At Close: May 17, 2024
- Late-breaking Poster Presentation on Sunday, October 3, 2021
CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms
Crinetics Pharmaceuticals to Participate in September Investor Conferences
07:30am, Tuesday, 07'th Sep 2021
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel th
Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer
07:30am, Thursday, 02'nd Sep 2021
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of n
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
04:02pm, Tuesday, 10'th Aug 2021
– Commenced dosing in Phase 3 PATHFNDR-1 study –
CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts
Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners
07:30am, Thursday, 29'th Jul 2021
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of nove
- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option -
Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel
08:30am, Wednesday, 16'th Jun 2021
SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of nov
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
04:05pm, Thursday, 06'th May 2021
Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
06:31pm, Wednesday, 07'th Apr 2021
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of nov
Crinetics Pharmaceuticals, Inc. (CRNX) CEO Scott Struthers on Q4 2020 Results - Earnings Call Transcript
10:24pm, Tuesday, 30'th Mar 2021
Crinetics Pharmaceuticals, Inc. (CRNX) CEO Scott Struthers on Q4 2020 Results - Earnings Call Transcript
Webcast and conference call to take place on Tuesday, March 30, 2021 at 4:30 p.m. ET Webcast and conference call to take place on Tuesday, March 30, 2021 at 4:30 p.m. ET
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs
07:10am, Friday, 12'th Mar 2021
- Details of New Paltusotine Tablet Formulation to be Unveiled -
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of nov
